Prelude Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Prelude TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 7.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 73.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 8.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -122.9% betragen.

Wichtige Informationen

-7.1%

Wachstumsrate der Gewinne

8.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	73.3%
Zukünftige Eigenkapitalrendite	-122.9%
Analystenabdeckung	Low
Zuletzt aktualisiert	08 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Sep 16

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 09

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Feb 03

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Sep 17

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 28

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Jan 28

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Mar 14

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Dec 14

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Jul 05

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Feb 16

Prelude Therapeutics prices $150M share offering

Jan 07

Prelude Therapeutics readies public offering

Jan 04

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

Dec 25

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:PRLD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-162	-136	N/A	2
12/31/2025	N/A	-153	-132	N/A	3
12/31/2024	N/A	-136	-125	N/A	2
9/30/2024	3	-132	-108	-106	N/A
6/30/2024	N/A	-130	-106	-104	N/A
3/31/2024	N/A	-126	-112	-109	N/A
12/31/2023	N/A	-122	-111	-107	N/A
9/30/2023	N/A	-117	-109	-106	N/A
6/30/2023	N/A	-117	-104	-101	N/A
3/31/2023	N/A	-114	-95	-92	N/A
12/31/2022	N/A	-115	-87	-84	N/A
9/30/2022	N/A	-120	-89	-87	N/A
6/30/2022	N/A	-120	-91	-88	N/A
3/31/2022	N/A	-120	-92	-89	N/A
12/31/2021	N/A	-112	-86	-84	N/A
9/30/2021	N/A	-98	-75	-73	N/A
6/30/2021	N/A	-84	-65	-63	N/A
3/31/2021	N/A	-69	-54	-52	N/A
12/31/2020	N/A	-57	-47	-46	N/A
9/30/2020	N/A	-48	-40	-40	N/A
6/30/2020	N/A	-38	-34	-33	N/A
3/31/2020	N/A	-32	-31	-30	N/A
12/31/2019	N/A	-28	-26	-26	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PRLD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PRLD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PRLD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: PRLD wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: PRLD wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: PRLD wird voraussichtlich in 3 Jahren unrentabel sein.

Prelude Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 12% to US$6.50

Price target decreased by 10.0% to US$5.40

Price target decreased by 9.7% to US$7.00

Price target decreased by 22% to US$7.75

Price target decreased to US$9.60

Price target decreased to US$11.60

Recent updates

Price target increased by 12% to US$6.50

Price target decreased by 10.0% to US$5.40

Prelude Therapeutics Incorporated Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

New minor risk - Market cap size

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Prelude Therapeutics Incorporated, Annual General Meeting, Jun 14, 2024

Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Insufficient new directors

Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding

Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding

New major risk - Revenue and earnings growth

Price target decreased by 9.7% to US$7.00

New minor risk - Market cap size

Price target decreased by 22% to US$7.75

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

New minor risk - Share price stability

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Founder recently bought US$67k worth of stock

President & Chief Medical Officer exercised options and sold US$81k worth of stock

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Founder recently bought US$98k worth of stock

Price target decreased to US$9.60

We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Prelude Therapeutics Incorporated Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

Prelude wins FDA clearance to start Phase 1 trial for cancer candidate

Prelude downgraded at Morgan Stanley ahead of key update

Price target decreased to US$11.60

We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from Russell 2000 Growth Index

Price target increased to US$30.00

Prelude Therapeutics Incorporated, Annual General Meeting, Jun 17, 2022

Price target decreased to US$25.25

Deborah Morosini Resigns as an Officer of Prelude Therapeutics Incorporated and Will Transition into a Role of Strategic Advisor to the President

Executive VP & Head of Chemistry exercised options to buy US$237k worth of stock.

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Price target increased to US$44.00

Price target decreased to US$38.00

Executive VP & Head of Chemistry recently bought US$95k worth of stock

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Chief Financial Officer Brian Piper has left the company

Insider exercised options and sold US$87k worth of stock

Price target decreased to US$47.20

Chief Medical Officer exercised options and sold US$436k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$77k worth of stock

Chief Medical Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$681k worth of stock

Chief Medical Officer exercised options and sold US$384k worth of stock

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from Russell 3000E Value Index

Chief Medical Officer exercised options and sold US$458k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$574k worth of stock

Chief Medical Officer exercised options and sold US$838k worth of stock

Chief Medical Officer exercised options and sold US$725k worth of stock

Chief Medical Officer notifies of intention to sell stock

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

New 90-day high: US$90.03

Prelude Therapeutics Incorporated Announces Board Changes

Independent Director has left the company

Prelude Therapeutics Incorporated has completed a Follow-on Equity Offering in the amount of $150 million.

Prelude Therapeutics prices $150M share offering

Prelude Therapeutics readies public offering

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares